Seeking Alpha

More on Myriad Genetics (MYGN): FQ2 easily beats Street estimates on a 21% Y/Y jump in total...

More on Myriad Genetics (MYGN): FQ2 easily beats Street estimates on a 21% Y/Y jump in total sales. Molecular diagnostic testing revenue +20%, Oncology +16%, and Women's Health +27% over the prior year period. The company raises FY13 guidance, now expecting to earn between $1.55 - $1.58 per share on revenue of around $575M to $585M. Street estimates are for an EPS of $1.54 on revenue of $580M. Shares +1.3% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector